Heritability of Caffeine Metabolism: Environmental Effects Masking Genetic Effects on CYP1A2 Activity but Not on NAT2

Clinical Pharmacology and Therapeutics

Volumn 100, Issue 6, 2016, Pages 606-616

  Matthaei, J ^a   Tzvetkov, M V ^a   Strube, J ^a   Sehrt, D ^a   Sachse Seeboth, C ^a   Hjelmborg, J B ^b   Moller S ^b   Halekoh, U ^b   Hofmann, U ^c   Schwab, M ^c,d,e   Kerb, R ^c   Brockmoller J ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^e UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; BREAST CANCER RESISTANCE PROTEIN; CAFFEINE; CONTRACEPTIVE AGENT; CYTOCHROME P450 1A2; CYP1A1 PROTEIN, HUMAN; CYP1A2 PROTEIN, HUMAN; CYTOCHROME P450 1A1; NAT2 PROTEIN, HUMAN; ORAL CONTRACEPTIVE AGENT;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DIETARY INTAKE; DIZYGOTIC TWINS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; DRUG TRANSFORMATION; ENVIRONMENTAL FACTOR; ENZYME ACTIVITY; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIATION; GENOTYPE; HEREDITY; HERITABILITY; HUMAN; HUMAN EXPERIMENT; MALE; METABOLITE; MONOZYGOTIC TWINS; NORMAL HUMAN; PHARMACOGENETICS; PHARMACOKINETIC PARAMETERS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN INTAKE; SMOKING; ADOLESCENT; AREA UNDER THE CURVE; ENVIRONMENT; GENETICS; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AREA UNDER CURVE; ARYLAMINE N-ACETYLTRANSFERASE; CAFFEINE; CONTRACEPTIVES, ORAL, HORMONAL; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP1A2; ENVIRONMENT; FEMALE; HUMANS; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, GENETIC; SMOKING; TWINS, DIZYGOTIC; TWINS, MONOZYGOTIC; YOUNG ADULT;

EID: 84994259443     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.444     Document Type: Article

References (51)

1. Aldridge, A., Aranda, J.V. & Neims, A.H. Caffeine metabolism in the newborn. Clin. Pharmacol. Ther. 25, 447–453 (1979).
2. Grant, D.M., Tang, B.K. & Kalow, W. Variability in caffeine metabolism. Clin. Pharmacol. Ther. 33, 591–602 (1983).
3. Rost, K.L., Brösicke, H., Brockmöller, J., Scheffler, M., Helge, H. & Roots, I. Increase of cytochrome P450IA2 activity by omeprazole: evidence by the 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin. Clin. Pharmacol. Ther. 52, 170–180 (1992).
4. Schrenk, D., Brockmeier, D., Mörike, K., Bock, K.W. & Eichelbaum, M. A distribution study of CYP1A2 phenotypes among smokers and non-smokers in a cohort of healthy Caucasian volunteers. Eur. J. Clin. Pharmacol. 53, 361–367 (1998).
5. Catteau, A., Bechtel, Y.C., Poisson, N., Bechtel, P.R. & Bonaiti-Pellie, C. A population and family study of CYP1A2 using caffeine urinary metabolites. Eur. J. Clin. Pharmacol. 47, 423–430 (1995).
6. Tantcheva-Poór, I., Zaigler, M., Rietbrock, S. & Fuhr, U. Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test. Pharmacogenetics 9, 131–144 (1999).
7. Rasmussen, B.B., Brix, T.H., Kyvik, K.O. & Brøsen, K. The interindividual differences in the 3-demthylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors. Pharmacogenetics 12, 473–478 (2002).
8. Gunes, A. et al. Influence of genetic polymorphisms, smoking, gender and age on CYP1A2 activity in a Turkish population. Pharmacogenomics 10, 769–778 (2009).
9. Perera, V., Gross, A.S. & McLachlan, A.J. Influence of environmental and genetic factors on CYP1A2 activity in individuals of South Asian and European ancestry. Clin. Pharmacol. Ther. 92, 511–519 (2012).
10. Wang, B. & Zhou, S.F. Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr. Med. Chem. 16, 4066–4218 (2009).
11. Butler, M.A., Iwasaki, M., Guengerich, F.P. & Kadlubar, F.F. Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc. Natl. Acad. Sci. USA 86, 7696–7700 (1989).
12. Zhu, B. et al. Assessment of cytochrome P450 activity by a five-drug cocktail approach. Clin. Pharmacol. Ther. 70, 455–461 (2001).
13. Turpault, S. et al. Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A. Br. J. Clin. Pharmacol. 68, 928–935 (2009).
14. Zhuang, Y. et al. Evaluation of disease-mediated therapeutic protein-drug interactions between an anti-interleukin-6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approach. J. Clin. Pharmacol. 55, 1386–1394 (2015).
15. Butler, M.A. et al. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 2, 116–127 (1992).
16. Fuhr, U. et al. Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations. Pharmacogenetics 6, 159–176 (1996).
17. Cascorbi, I., Brockmöller, J., Mrozikiewicz, P.M., Müller, A. & Roots, I. Arylamine N-acetyltransferase activity in man. Drug Metab. Rev. 31, 489–502 (1999).
18. Kalow, W. & Tang, B.K. Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities. Clin. Pharmacol. Ther. 50(5 Pt 1), 508–519 (1991).
19. Tang, B.K., Kadar, D., Qian, L., Iriah, J., Yip, J. & Kalow, W. Caffeine as a metabolic probe: validation of its use for acetylator phenotyping. Clin. Pharmacol. Ther. 49, 648–657 (1991).
20. Kimura, M. et al. Cyp2a6 is a principal enzyme involved in hydroxylation of 1,7-dimethylxanthine, a main caffeine metabolite, in humans. Drug Metab. Dispos. 33, 1361–1366 (2005).
21. Abraham, K., Geusau, A., Tosun, Y., Helge, H., Bauer, S. & Brockmöller, J. Severe 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) intoxication: insights into the measurement of hepatic cytochrome P450 1A2 induction. Clin. Pharmacol. Ther. 72, 163–174 (2002).
22. Sachse, C., Brockmöller, J., Bauer, S. & Roots, I. Functional significance of a C-->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br. J. Clin. Pharmacol. 47, 445–449 (1999).
23. Ghotbi, R., Christensen, M., Roh, H.K., Ingelman-Sundberg, M., Aklillu, E. & Bertilsson, L. Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans. Eur. J. Clin. Pharmacol. 63, 537–546 (2007).
24. Sachse, C. et al. Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism. Br. J. Clin. Pharmacol. 55, 68–76 (2003).
25. Cornelis, M.C. et al. Genome-wide meta-analysis identifies regions on 7p21 (AHR) and 15q24 (CYP1A2) as determinants of habitual caffeine consumption. PLoS Genet. 7, e1002033 (2011).
26. Amin, N. et al. Genome-wide association analysis of coffee drinking suggests association with CYP1A1/CYP1A2 and NRCAM. Mol. Psychiatry 17, 1116–1129 (2012).
27. Coffee and Caffeine Genetics Consortium, et al. Genome-wide meta-analysis identifies six novel loci associated with habitual coffee consumption. Mol. Psychiatry 20, 647–656 (2015).
28. Boomsma, D., Busjahn, A. & Peltonen, L. Classical twin studies and beyond. Nat. Rev. Genet. 3, 872–882 (2002).
29. Cascorbi, I., Drakoulis, N., Brockmöller, J., Maurer, A., Sperling, K. & Roots, I. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am. J. Hum. Genet. 57, 581–592 (1995).
30. Kinzig-Schippers, M. et al. Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses? Antimicrob. Agents Chemother. 49, 1733–1738 (2005).
31. Kalow, W., Tang, B.K. & Endrenyi, L. Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research. Pharmacogenetics 8, 283–289 (1998).
32. Ozdemir, V. et al. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 10, 373–388 (2000).
33. Rijsdijk, F.V. & Sham, P.C. Analytic approaches to twin data using structural equation models. Brief. Bioinform. 3, 119–133 (2002).
34. Perera, V., Gross, A.S., Xu, H. & McLachlan, A.J. Pharmacokinetics of caffeine in plasma and saliva, and the influence of caffeine abstinence on CYP1A2 metrics. J. Pharm. Pharmacol. 63, 1161–1168 (2011).
35. Benowitz, N.L., Peng, M. & Jacob, P. 3rd. Effects of cigarette smoking and carbon monoxide on chlorzoxazone and caffeine metabolism. Clin. Pharmacol. Ther. 74, 468–474 (2003).
36. Granfors, M.T., Backman, J.T., Laitila, J. & Neuvonen, P.J. Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2. Clin. Pharmacol. Ther. 78, 400–411 (2005).
37. Yang, A., Palmer, A.A. & de Wit, H. Genetics of caffeine consumption and responses to caffeine. Psychopharmacology (Berl) 211, 245–257 (2010).
38. Cornelis, M.C., El-Sohemy, A., Kabagambe, E.K. & Campos, H. Coffee, CYP1A2 genotype, and risk of myocardial infarction. JAMA 295, 1135–1141 (2006).
39. Grant, D.M., Goodfellow, G.H., Sugamori, K.S. & Durette, K. Pharmacogenetics of the human arylamine N-acetyltransferases. Pharmacology 61, 204–211 (2000).
40. Sim, E. et al. Arylamine N-acetyltransferases: structural and functional implications of polymorphisms. Toxicology 254, 170–183 (2008).
41. Hein, D.W. & Doll, M.A. Accuracy of various human NAT2 SNP genotyping panels to infer rapid, intermediate and slow acetylator phenotypes. Pharmacogenomics 13, 31–41 (2012).
42. Freedman, N.D., Park, Y., Abnet, C.C., Hollenbeck, A.R. & Sinha, R. Association of coffee drinking with total and cause-specific mortality. N. Engl. J. Med. 366, 1891–1904 (2012).
43. Saito, E. et al. Association of coffee intake with total and cause-specific mortality in a Japanese population: the Japan Public Health Center-based Prospective Study. Am. J. Clin. Nutr. 101, 1029–1037 (2015).
44. Ding, M. et al. Association of coffee consumption with total and cause-specific mortality in 3 large prospective cohorts. Circulation 132, 2305–2315 (2015).
45. Winkler, G. & Döring, A. Validation of a short qualitative food frequency list used in several German large scale surveys. Z Ernahrungswiss 37, 234–241 (1998).
46. Matthaei, J. et al. Heritability of metoprolol and torsemide pharmacokinetics. Clin. Pharmacol. Ther. 98, 611–621 (2015).
47. Nyéki, A., Buclin, T., Biollaz, J. & Decosterd, L.A. NAT2 and CYP1A2 phenotyping with caffeine: head-to-head comparison of AFMU vs. AAMU in the urine metabolite ratios. Br. J. Clin. Pharmacol. 55, 62–67 (2003).
48. Jetter, A. et al. Phenotyping of N-acetyltransferase type 2 by caffeine from uncontrolled dietary exposure. Eur. J. Clin. Pharmacol. 60, 17–21 (2004).
49. Sham, P.C. Statistics in Human Genetics (Arnold, John Wiley and Sons, New York: London, 1998).
50. Holst, K. & Scheike, T. Mets: analysis of multivariate event times, R package version 1.1.1. (2015).
51. R-Core Team. R: a language and environment for statistical computing, R foundation for statistical computing. Vienna, Austria. (2015).